

Supplementary Table S1. Baseline characteristics of the study cohort.

Characteristic	N = 33
Age at first ICI (yrs) median (IQR)	62 (49, 74)
Sex, n (%)	
Female	16 (48%)
Male	17 (52%)
Race, n (%)	
White	31 (97%)
Other	1 (3%)
Smoking, n (%)	
Active	3 (9%)
Former	11 (34%)
Never	18 (57%)
Tumor Grade, n (%)	
G1	1 (3%)
G2	16 (50%)
G3	15 (47%)
Primary Tumor Site, n (%)	
Left	13 (39%)
Right	20 (61%)
KRAS, n (%)	
Mutated	9 (31%)
WT	20 (69%)
BRAF ^{V600E} , n (%)	
Present	8 (28%)
Absent	21 (72%)
MLH1 protein Loss, n (%)	
No	10 (33%)
Yes	21 (67%)
MSH2 protein Loss, n (%)	
No	25 (81%)
Yes	6 (19%)
MSH6 protein Loss, n (%)	
No	20 (65%)
Yes	11 (35%)
PMS2 protein Loss, n (%)	
No	9 (29%)
Yes	22 (71%)

Characteristic	N = 33
Number of Metastatic Sites, n (%)	
1	4 (13%)
2	14 (45%)
3+	13 (42%)
Metastatic Site, n (%)	
Liver Involved	19 (59%)
Lung Involved	7 (22%)
Number of Prior Regimens, n (%)	
0	10 (30%)
1	15 (46%)
2	5 (15%)
<u>>3</u>	3 (9%)
PFS Status, n (%)	
Censored	13 (39%)
Event	20 (61%)
PFS (Months), median (95%CI)	28.4 (9.8, NR)
Tumor response*, n (%)	
Complete response	11 (33%)
Partial response	3 (9%)
Stable disease	1 (3%)
Disease Progression	18 (55%)
Objective response rate	42%

NR, not reached; *determined at date of last follow-up

